Moreover, it has been suggested that CD229 could have a relevant biological role in the survival of myeloma cells [25], and that its expression is higher in myeloma-propagating cells, which are more quiescent, and more drug-resistant than the common malignant plasma cell [26]. Here, LY9 is linked to plasma cell myeloma.